CYAD [NASD]
Celyad Oncology SA
Index- P/E- EPS (ttm)-1.51 Insider Own- Shs Outstand22.59M Perf Week-33.51%
Market Cap31.78M Forward P/E- EPS next Y- Insider Trans- Shs Float22.59M Perf Month122.41%
Income- PEG- EPS next Q- Inst Own29.13% Short Float / Ratio0.57% / 0.09 Perf Quarter19.44%
Sales- P/S- EPS this Y- Inst Trans- Short Interest0.13M Perf Half Y-17.83%
Book/sh1.36 P/B0.95 EPS next Y- ROA- Target Price- Perf Year-66.75%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.46 - 3.65 Perf YTD161.72%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-64.66% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low180.19% ATR0.31
Employees95 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)50.59 Volatility20.49% 21.84%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.10 Prev Close1.57
ShortableNo LT Debt/Eq- EarningsNov 10 BMO Payout- Avg Volume1.49M Price1.29
Recom3.00 SMA2014.15% SMA5024.87% SMA200-18.88% Volume150,692 Change-17.83%
Jul-05-19Reiterated H.C. Wainwright Buy $52 → $48
May-25-18Initiated Wells Fargo Outperform $44
Dec-21-22 09:12AM
01:00AM
01:00AM
Nov-10-22 01:01AM
01:01AM
01:00AM Loading…
Oct-12-22 01:00AM
Sep-20-22 01:02AM
Aug-05-22 01:00AM
01:00AM
Aug-01-22 05:54AM
01:01AM
Jul-28-22 01:05AM
01:00AM
Jun-24-22 01:05AM
01:03AM
02:00AM Loading…
May-31-22 02:00AM
02:00AM
May-25-22 12:00PM
May-17-22 04:05PM
04:01PM
May-05-22 06:12PM
05:31PM
04:05PM
04:01PM
Mar-24-22 04:05PM
04:02PM
Mar-17-22 07:00AM
02:01AM
Mar-02-22 02:30AM
02:30AM
06:32AM Loading…
Feb-28-22 06:32AM
02:32AM
Jan-31-22 04:05PM
Jan-20-22 09:40AM
Jan-10-22 01:01AM
Dec-31-21 01:50PM
01:01AM
01:00AM
Dec-22-21 01:02AM
01:00AM
Dec-17-21 04:05PM
Dec-16-21 01:00AM
Dec-15-21 01:01AM
01:00AM
Dec-13-21 01:01AM
01:00AM
Dec-08-21 04:05PM
04:02PM
Dec-03-21 11:17AM
07:32AM
01:31AM
Nov-12-21 07:00AM
07:00AM
Nov-10-21 04:05PM
Nov-04-21 09:01AM
Nov-02-21 03:00AM
Oct-29-21 04:05PM
04:05PM
Oct-01-21 08:00AM
08:00AM
Sep-01-21 01:00AM
01:00AM
Aug-04-21 04:01PM
Jul-30-21 01:00AM
01:00AM
Jul-29-21 01:00AM
Jul-20-21 04:01PM
04:01PM
Jul-13-21 04:01PM
04:00PM
Jul-07-21 04:01PM
04:00PM
Jun-30-21 01:00AM
01:00AM
Jun-11-21 02:59AM
02:59AM
May-31-21 01:00AM
May-26-21 01:00AM
May-19-21 01:00AM
May-13-21 06:52AM
May-12-21 04:01PM
May-06-21 04:01PM
May-05-21 01:00AM
May-04-21 01:00AM
Apr-30-21 01:00AM
Apr-19-21 01:00AM
Apr-01-21 01:00AM
Mar-31-21 01:00AM
Mar-25-21 11:15AM
Mar-24-21 04:01PM
Mar-18-21 02:00AM
Mar-01-21 04:01PM
Feb-02-21 01:00AM
Jan-20-21 04:05PM
04:01PM
Jan-18-21 01:00AM
Jan-11-21 04:01PM
Jan-07-21 01:00AM
Jan-05-21 01:00AM
Dec-15-20 04:01PM
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.